NCT06816888 (Echo Prompts) is a NA clinical trial of No Prompt in Mitral Regurgitation (MR), sponsored by Ottawa Heart Institute Research Corporation.

Who is sponsoring NCT06816888?

NCT06816888 is sponsored by Ottawa Heart Institute Research Corporation.

What drugs are being tested in NCT06816888?

Interventions in NCT06816888: No Prompt, Prompt 1, Prompt 2.

Is NCT06816888 still recruiting?

NCT06816888 is currently active, enrolled. Last updated 10 February 2025.

Last reviewed 2025-02-10 · How we verify

NCT06816888: Echo Prompts

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of Automatic Prompts in Echocardiographic Reports on Referral to Cardiology

Active, enrolled NA Last updated 10 February 2025

What this trial tests

NA trial testing No Prompt in Mitral Regurgitation (MR) in 300 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

30 January 2025

Primary endpoint
1 February 2026

1 May 2026

Quick facts

Lead sponsor	Ottawa Heart Institute Research Corporation
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	health services research
Enrollment	300
Start date	30 January 2025
Primary completion	1 February 2026
Estimated completion	1 May 2026
Sites	1 location across Canada

Drugs / interventions tested

No Prompt
Prompt 1
Prompt 2

Conditions studied

Mitral Regurgitation (MR) — all drugs for Mitral Regurgitation (MR) →
Moderate or Severe Aortic Stenosis (AS) (Mean Pressure Gradient ≥ 20 mm Hg or Aortic Valve Area ≤ 1.5 cm2) — all drugs for Moderate or Severe Aortic Stenosis (AS) (Mean Pressure Gradient ≥ 20 mm Hg or Aortic Valve Area ≤ 1.5 cm2) →

Sponsor

Ottawa Heart Institute Research Corporation

Who can join

18 and older, any sex, with Mitral Regurgitation (MR) or Moderate or Severe Aortic Stenosis (AS) (Mean Pressure Gradient ≥ 20 mm Hg or Aortic Valve Area ≤ 1.5 cm2). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Echo Prompts study is a multi-center randomized controlled study to evaluate the impact of automatic prompts added to the conclusion of the echocardiographic reports of patient diagnosed with significant VHD 1) suggesting referral to a cardiologist or 2) suggesting referral to a cardiologist and offering the help of the University of Ottawa Heart Institute Center for Valvular Heart Diseases, compared to current standard of care (no prompts) on the rates and time to an evaluation by a cardiologist. We plan to involve a total of 300 patients in total. Primary endpoint will be the rate of referrals of patients having VHD to a cardiologist within 6 months after their TTE.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Mitral Regurgitation (MR)

Currently open trials in the same condition.

NCT07197736 — DELINEATE-Prospective · recruiting
NCT07501234 — Safety and Feasibility Study of the MitraFix® Transcatheter Mitral Valve System · NA · recruiting
NCT06876883 — MItral Regurgitation Risk Assessment and CLinical modElling · recruiting
NCT07045753 — The Prospective Segeberg Registry for Mitral Transcatheter Edge-to-Edge Repair · recruiting

Other Ottawa Heart Institute Research Corporation trials

Trials by the same sponsor.

NCT06907251 — Dapagliflozin for Long COVID Syndrome · Phase 3 · not yet recruiting
NCT07002450 — Left Atrial Imaging Prior to Cardioversion: Leveraging Computed Tomography to Rule Out Thrombus in The Emergency Departm · NA · recruiting
NCT06832085 — Combination Nicotine Replacement Therapy, Cytisine, or Varenicline for Smoking Cessation · Phase 4 · recruiting
NCT06556667 — MAX - SHOCK Clinical Trial · NA · recruiting
NCT06494163 — Exercise Training in Women With Heart Disease 2 · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06816888 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ottawa Heart Institute Research Corporation
Last refreshed: 10 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06816888.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing